Guy W. Neff, Christopher B. O'Brien, Jose Nery, Norah Shire, Marzia Montalbano, Phillip Ruiz, Ciao Nery, Kamran Safdar, Maria De Medina, Andreas G. Tzakis, Eugene R. Schiff, Juan Madariaga – 20 October 2004 – Hepatitis B virus (HBV) recurrence following liver transplantation (LTx) has been controllable primarily with the use of hepatitis B immune globulin (HBIg) and lamivudine (LAM). However, HBV resistance to LAM and/or HBIg has become an increasing problem prompting the use of newer antiviral agents.

Dianne LaPointe Rudow, Robert S. Brown, Jean C. Emond, Douglas Marratta, Sarah Bellemare, Milan Kinkhabwala – 20 October 2004 – Live donors are becoming an increasingly important source of donor organs in liver transplantation; however, long‐term functional aspects of recovery from donor right hepatectomy are unknown. We analyzed donor outcomes at 1‐year follow‐up. We performed a single‐center retrospective analysis of 70 right hepatectomy donors. Six‐week and 1‐year postoperative follow‐up results were compared to preoperative baseline values.

David Axelrod, Alan Koffron, Andre DeWolf, Alfred Baker, John Fryer, Talia Baker, James Frederiksen, Keith Horvath, Micheal Abecassis – 20 October 2004 – Advanced coronary artery disease (CAD) is increasingly common in patients awaiting orthotopic liver transplantation (OLT). Unfortunately, in patients whose coronary artery anatomy is not amenable to angioplasty, coronary artery bypass grafting (CABG) alone may precipitate hepatic decompensation. Thus, combined liver transplant and coronary artery bypass grafting (CABG‐OLT) may be required to effectively treat both conditions.

Christina Chan, François Berthiaume, Bharath D. Nath, Arno W. Tilles, Mehmet Toner, Martin L. Yarmush – 20 October 2004 – The severe donor liver shortage, high cost, and complexity of orthotopic liver transplantation have prompted the search for alternative treatment strategies for end‐stage liver disease, which would require less donor material, be cheaper, and less invasive.

20 October 2004

Álvaro Antônio Bandeira Ferraz, Marcelo José Antunes Sette, Marcelo Maia, Edmundo Pessoa de Almeida Lopes, Michelle Maria Gonsalves Godoy, André Tavares da Silva Petribú, Marconi Meira, Otávio da Rosa Borges – 20 October 2004

Jessica Y. Leung, Andrew X. Zhu, Fredric D. Gordon, Daniel S. Pratt, Abigail Mithoefer, Kathryn Garrigan, Adam Terella, Martin Hertl, A. Benedict Cosimi, Raymond T. Chung – 20 October 2004 – The incidence of hepatocellular carcinoma (HCC), a frequent and incurable complication of cirrhosis, continues to rise. Orthotopic liver transplantation (OLT) has been proposed as a treatment for unresectable, intrahepatic HCC limited in extent to the Milan criteria adopted by the United Network of Organ Sharing (UNOS) in 1998.

Miguel Lebrón Gallardo, Manuel E. Herrera Gutierrez, Gemma Seller Pérez, Emilio Curiel Balsera, Juan F. Fernández Ortega, Guillermo Quesada García – 20 October 2004 – Renal dysfunction (RD) is a frequent complication after orthotopic liver transplantation (OLT), and it has an unfavorable effect on the prognosis of OLT patients. The purpose of our study was to identify possible risk factors for RD and its impact on survival.

Angelo Andriulli, Ilario de Sio, Luigi Solmi, Luciano De Carlis, Roberto Troisi, Alessandro Grasso, Virginia Festa, Eugenio Caturelli, Alessandro Giacomoni, Camillo Del Vecchio Blanco, Bernard De Hemptinne, Andrew Burroughs, Francesco Perri – 20 October 2004 – For “early” hepatocellular carcinoma (HCC), surgery, orthotopic liver transplantation (OLT) and percutaneous ethanol injection (PEI) improve the natural history of the disease. We performed a retrospective study to evaluate the outcome of patients with cirrhosis and early HCC treated by PEI (n = 417) or OLT (n = 172).

Alberto Grassi, Micaela Susca, Matteo Ravaioli, Gian Luca Grazi, Antonia D'Errico, Andrea Bontadini, Daniela Zauli, Antonio Pinna, Francesco B. Bianchi, Giorgio Ballardini – 20 October 2004 – Engraftment by recipient's (R) cells has been already demonstrated in gender mismatched liver grafts using fluorescence in situ hybridization (FISH), with contrasting results concerning epithelial cells. Mismatch for human leukocyte antigen (HLA) class I (HLA‐I) is quite common in patients with orthotopic liver transplantation (OLT).